NVS241115C125000
- 0.04
- 0.000.00%
Novartis AG Newsroom
Novartis Is Maintained at Market Perform by BMO Capital
Novartis Analyst Ratings
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating
BMO Capital Maintains Novartis AG(NVS.US) With Hold Rating, Raises Target Price to $120
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
Hold Rating for Novartis AG Amid Balanced Outlook and Patent Risks
LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Street's "Strong Buy" Rating?
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $125
Citi Sticks to Its Hold Rating for Novartis AG (NOVN)
Goldman Sachs Remains a Hold on Novartis AG (NOVN)
Novartis AG: Hold Rating Justified Amid Kisqali's Market Potential and FDA Approval
Buy Rating Affirmed: Novartis AG's Strong Growth Outlook and Underestimated Pipeline Potential
Novartis AG (NOVN) Receives a Buy From UBS
Novartis Lower as BofA Downgrades on Risks to Valuation
Novartis Analyst Ratings
B of A Securities Downgrades Novartis to Neutral, Lowers Price Target to $130
BofA Securities Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $130
BMO Capital Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $118
Erste Group Maintains Novartis AG(NVS.US) With Buy Rating
Novartis Analyst Ratings